WO2012158002A1 - Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием - Google Patents
Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием Download PDFInfo
- Publication number
- WO2012158002A1 WO2012158002A1 PCT/KZ2011/000018 KZ2011000018W WO2012158002A1 WO 2012158002 A1 WO2012158002 A1 WO 2012158002A1 KZ 2011000018 W KZ2011000018 W KZ 2011000018W WO 2012158002 A1 WO2012158002 A1 WO 2012158002A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- iodine
- renessans
- starch
- mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/12—Iodine, e.g. iodophors; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the invention relates to the pharmaceutical industry, namely to the production of iodine-containing drugs.
- Iodine preparations currently occupy an important place among modern antiseptics.
- the causative agents of many infections are sensitive to iodine-containing drugs that exhibit fungicidal, cytocidal, antiprotozoal effects, are active against some spores and do not form acquired resistance to them.
- iodine significantly loses toxicity, acts more slowly and longer (within 5 hours), while maintaining antiviral and antimicrobial properties (Nikulin V.N., Gerasimenko V.V., 2008; Svirskaya E ., 2008).
- Iodine also exhibits fungicidal, cystocidal. antiprotozoal effect, has activity against some spores. With a resorptive effect, it actively participates in the metabolic processes of the body, increases the lecithin-cholesterol coefficient, lipoproteinase and fibrinolytic activity of the blood; slows down blood coagulation; lowers cholesterol and ⁇ -lipoproteins.
- iodine with polymers iodinol, iodanate, iodovidone, povidone-iodine, iodopyron, iodoform, hiniofon
- iodine with polymers iodinol, iodanate, iodovidone, povidone-iodine, iodopyron, iodoform, hiniofon
- povidone-iodine iodine in the form of a complex with the binding iodophore - polyvinylpyrrolidone
- povidone-iodine has a greater spectrum of antibacterial and antiviral effects than other known antiseptics. It is active against many types of viruses, including HIV, in in vitro suspension experiments [Kawana R. et al., Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. - Dermatology, 1997r., 195, App. 2, pp. 29-35].
- Anti-infective agents containing povidone iodine can be used to combat diseases caused by HIV, chlamydia, gonococcus, treponema and herpes simplex virus [Tsutomu S., Junko S. Anti-infective against STD relating, for example, to HIV, Chlamidia, gonococcus, treponema pallidum or herpes simplex and device used to preserve / mix principal ingredient and base of such anti-infective - EP 0823996A1, A 01N 59/12, A 61 K 9/00, application. 08/15/96, publ. 02/18/98 and Shanbrom E.
- the known drug Iodomidol with antiviral and antibacterial action [patent of the Republic of Ukraine Jfs 6730, application. 01/26/96, publ. 16.1 1.98], containing iodine, potassium or sodium iodide, a synthetic water-soluble polymer acting as a polymer matrix, a mixture of natural polymers, for example poly-, mono- and oligosaccharides, as well as water in the following ratio, g / l: iodine 6-10 , potassium or sodium iodide 9-15, synthetic water-soluble polymer 2-4, mono-, oligo- and polysaccharides 8-120, water and the rest.
- This drug has a relatively high toxicity and is intended solely for the treatment of viral and other bacterial diseases of animals.
- a medicinal product having a bactericidal and virucidal effect containing iodine, potassium or sodium iodide, a synthetic water-soluble polymer, natural polymers, for example polysaccharides, and mono- and oligosaccharides, in the following ratio of components, g / l: iodine 6-10, iodide potassium or sodium 9-15, synthetic water-soluble polymer 2-4, natural polymer (polysaccharides) and mono- and oligosaccharides 8-120, water and the rest (CZ 5435, A 61K 33/18, A 61 31/715).
- the disadvantage of this drug is its relatively high toxicity. It is difficult to act on viruses that have already entered cells, since the cell itself reliably protects them from any effect. It is in the cell that the adapted virus is destructive. The problem is to suppress specific processes of the biological synthesis of viral particles at the molecular level without affecting, as far as possible, the life of the cells not infected with the virus.
- the Renaissance balm contains (wt.%) 0.5-1, 5 iodine, 1, 5-1, 7 potassium iodide, 14.0-16.0 starch, 2.0-3.0 glucose, 8.0 -10.0 glycerol, 2.0-3.0 lactic acid, 0.8-1.0 sodium chloride, 2.0-3.0 apple cider vinegar, and the rest, distilled water.
- balm is a biologically active additive, without an identified bactericidal effect against mycobacteria and is characterized by low bactericidal activity against spores, spore-forming bacteria and fungi.
- the balm is intended for oral use only and excludes
- the objective of the invention is the creation of a medicinal product with antibacterial, antiulcer and immunomodulatory effects of low toxicity with the possibility of its use in injectable form, as well as a method for its preparation.
- the technical result of the invention is the expansion of the range of drugs antibacterial, antiulcer and immunomodulatory effects of low toxicity with the possibility of use in the form of injections.
- a medicinal product including iodine, potassium iodide starch, ascorbic acid, glucose, sodium chloride and purified water in the following ratio of components (mass%):
- compositions namely, iodine, potassium iodide, starch, ascorbic acid glucose and sodium chloride in an aqueous solution. It contains fewer components, namely 6, relative to the prototype, which consists of 9 components.
- the distinctive features of the claimed composition from the prototype is the composition and concentration components.
- One of the main functions of the components used in the composition of the drug is to form a special structure that preserves the oxidative ability of iodine in some moderate state so that it is possible to transport these particles over long distances for its distribution throughout the body.
- the formation of this system provides the optimal composition with the following ratio of components (May%): iodine - 0.4 - 2.0; potassium iodide - 0.8 - 4.0; starch - 10.0-40.0; ascobic acid - 0.4-2.0; glucose - 1, 2 - 4.8; sodium chloride - 0.3-1.8, distilled water - the rest.
- the specified composition and certain concentrations of the components in the aqueous solution form the iodine-polymer complex, which acts as a matrix and forms associates, from which the active active agent, the active form of iodine, is released.
- Starch and glucose participate in the formation of the matrix and associates, i.e. poly- and monosugar having functional groups of different activity.
- the introduction of potassium iodide into the drug the formation of a physico-chemical system that for a long time prevents the deactivation of the main active agent.
- carbohydrates are essential components of bacterial cell walls, the first to come into contact with the immune system of a macroorganism. Due to this fact, innate immunity mechanisms include the steps of recognizing bacterial carbohydrates and glycoconjugates associated with the function of a number of lectin-type cellular receptors recently discovered on the surface of phagocytic cells.
- starch colloidal solution (starch paste) is prepared by stirring in a small amount of water, and gradually poured into boiling water with strong stirring.
- amylose-iodine complex is associated with the spiral conformation of the amylose chain, in the center of the spiral of which a channel-shaped cavity is formed with dimensions sufficient to accommodate iodine molecules.
- the starch-iodine complex forms hexagonal crystals. It was found that the formation of an iodine complex does not change the viscosity of amylose solutions.
- the components of the preparation provide selective oxidation by the main active agent, iodine, of the vital molecular components of viruses and bacteria.
- the components of the claimed drug are aimed at maintaining its stability and structure, and on the other, are responsible for the direct manifestation of two main properties: antimicrobial and immunomodulating, since the composition of the proposed drug optimally combines both antimicrobial components and immunomodulatory effects.
- the essential features of the RENESSANS drug provide the circulation of the drug in the body in an active state, which allows it to be used in injectable form.
- the method of preparation of the drug "RENESSANS” is as follows. Solutions of crystalline iodide and potassium iodide, sodium chloride and ascorbic acid in distilled water are prepared, as well as a suspension of starch in water. All solutions are mixed and adjusted to 1 liter of water.
- South crystalline iodine is crushed and 16 g of potassium iodide are dissolved in a small amount of purified water.
- Purified water is added to 150 g of starch to prepare a suspension.
- Solutions of sodium chloride (9.0 g) and ascorbic acid (10.0 g) are prepared, all are mixed and adjusted to one liter with purified water.
- the prepared drug has the appearance of a syrupy liquid, color from black to dark blue with a smell characteristic of iodine preparations.
- RENESSANS examples confirming the properties and possible use of the drug "RENESSANS”.
- RENESSANS To study the safety of the use of the drug RENESSANS, it was administered intraperitoneally to animals in various doses in undiluted form and diluted in physiological saline. When selecting a dose, we were guided by recommendations on the maximum allowable amounts of fluid for administration into the abdominal cavity, which for rats is 5 ml. The choice of dose for injection was determined according to the classification of toxicity of chemicals in accordance with GOST 12.1.007-76. The drug was administered daily once intraperitoneally.
- rats were divided into control and experimental groups.
- the drug was administered to animals intraperitoneally with dilution in physiological solution of sodium chloride, as well as undiluted.
- the studied drug "RENESSANS” did not cause statistically significant changes on the part of the blood cells of experimental animals, compared with control rats, therefore, the studied drug did not have a toxic effect on the blood system.
- the results of a histological examination of the organs of animals of the control and experimental groups showed that the RENESSANS preparation did not cause changes in the histological structure of the internal organs of experimental animals, which also confirms the non-toxicity of the drug.
- concentration of molecular iodine in solutions ranged from 0.27 to 1%, the concentration of iodine polysaccharide was about 1%,
- the initial solutions were diluted with physiological sodium chloride solution.
- each dilution of the preparation was plated on meat peptone agar in Petri dishes.
- RENESSANS ulcer healing was observed in 9 cases, regardless of their location (4 — gastric ulcers: media gastric and antral, and 5 ulcers
- lymphocytes venous blood of the total number of leukocytes, lymphocytes, leukoformula, the relative and absolute contents of the main subpopulations of lymphocytes (total T-lymphocytes, their helper and suppressor subpopulations of B-lymphocytes, natural killers), non-specific functional activity of T-lymphocytes, levels of the main classes of serum immunoglobulins and circulating immune complexes, phagocytic and functional-metabolic activity of neutrophilic leukocytes).
- the main subpopulations of lymphocytes were identified using commercial kits.
- the proposed drug "RENESSANS” can be used both for internal use and for injection. It was found that the antimicrobial effect is not only comparable to the action of aqueous solutions of iodine, but also in some cases exceeds them. The results of the assessment of the immune status during the testing of the drug showed the presence of an immunocorrective effect.
- the optimal dosage forms of the RENESSANS preparation are a suspension for oral administration and a suspension for injection.
- the drug "RENESSANS” is non-toxic, has an antimicrobial effect, antiulcer effect and immunocorrective properties.
- pH From 3.0 to 5.0 (potentiometric, GF XI, issue 1, p. 1 13).
- Microbiological purity The presence of bacteria of the Enterobacteliaceae family, Pseudomonas aeruginosa and Staphylococcus aureus is not allowed.
- pH From 3.0 to 5.0 (potentiometric, GF XI, issue 1, p. 1 13).
- the drug is sterile.
- the tests are carried out by the Direct sowing method in accordance with the requirements of the Global Fund XI, issue 2, p. 187.
- Test dose is 0.1 mg of the drug, diluted in 1 ml of water for injection per 1 kg of animal weight, intravenously (GF XI, issue 2, p. 183).
- Toxicity The drug is non-toxic.
- Test dose 0.1 mg diluted in 0.5 ml of water for injection, intravenously (GF XI, issue 2, p. 182). The observation period is 48 hours.
- the shelf life of the drugs for intravenous use and for injection was determined according to all parameters of quality and quantitative determination and the shelf life for both drugs was set at 2 years.
- Solutions of starch iodide and iodamylose were prepared by the action of the calculated amount of potassium polyiodide in 0.2-1% polysaccharide solutions.
- concentration of molecular iodine in solutions ranged from 0.27 to 1%, the concentration of iodine polysaccharide was about 1%.
- the initial solutions were diluted with physiological sodium chloride solution.
- To each dilution of iodine polysaccharide was added a suspension of bacteria in physiological saline in the amount of 5 mln cells prepared on the daily agar culture of the test strain. After a 15-minute exposure, each meat dilution was seeded with meat-peptone agar in Petri dishes.
- Evaluation of the immune status included: determination in the peripheral (venous) blood of the total number of leukocytes, lymphocytes, leukoformula, the relative and absolute contents of the main subpopulations of lymphocytes (total T-lymphocytes, their helper and suppressor subpopulations, B-lymphocytes, natural killers), non-specific functional activity T-lymphocytes, levels of the main classes of serum immunoglobulins and circulating immune complexes, phagocytic and functional-metabolic activity of neutrophilic leukocytes s).
- the main subpopulations of lymphocytes were identified using commercial sets of monoclonal antibodies to clusters of SVZ +, SV4 +, SV8 + -, SV 16+, SV72 + (Russian-made) by indirect immunofluorescence microscope using a Lumam I-3 microscope; nonspecific functional activity of T-lymphocytes was studied using a direct inhibition of leukocyte migration (RTML) during stimulation of PHA-R cells; the concentration of the main classes of serum immunoglobulins (M, G, A).
- RTML leukocyte migration
- class M serum immunoglobulin values which showed a statistically significant increase in its concentration (from 0.63 + 0.08 g / l to 0.984-0.07 g / l).
- rats were divided into control and experimental groups.
- the drug was administered to animals intraperitoneally with dilution in physiological solution of sodium chloride, as well as in undiluted form.
- the studied drug did not cause statistically significant changes in the blood elements of experimental animals, compared with control rats, therefore, the studied drug did not have a toxic effect on the blood system.
- the results of a histological examination of the animal organs of the control and experimental groups showed that the RENESSANS preparation did not cause changes in the histological structure of the internal organs of experimental animals, which also indicates the non-toxicity of the studied drug.
- the developed drug “RENESSANS” has antibacterial, antiulcer and immunomodulating effects with low toxicity and the possibility of injection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Pest Control & Pesticides (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014511314A JP2014513721A (ja) | 2011-05-16 | 2011-11-10 | 抗菌性、抗潰瘍性及び免疫調整作用を有する医薬組成物”renessans” |
EA201300096A EA021496B1 (ru) | 2011-05-16 | 2011-11-10 | Лекарственный препарат, обладающий противовирусным и антибактериальным действием |
KR1020137033138A KR20140033123A (ko) | 2011-05-16 | 2011-11-10 | 항바이러스성, 항궤양 및 면역 자극 작용을 가지고, 르네상스라는 이름을 가지는 의학 조제물 |
EP11865767.5A EP2606885B1 (en) | 2011-05-16 | 2011-11-10 | Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action |
CN201180070015.XA CN103561735B (zh) | 2011-05-16 | 2011-11-10 | 具有抗菌、抗溃疡和免疫调节作用的药物制剂 |
US14/117,857 US20140072598A1 (en) | 2011-05-16 | 2011-11-10 | Medicinal preparation "renessans" having an antibacterial, anti-ulcerous and immuno-modulating action |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KZ20110501 | 2011-05-16 | ||
KZ2011/0501.1 | 2011-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012158002A1 true WO2012158002A1 (ru) | 2012-11-22 |
Family
ID=47177155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KZ2011/000018 WO2012158002A1 (ru) | 2011-05-16 | 2011-11-10 | Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием |
Country Status (7)
Country | Link |
---|---|
US (1) | US20140072598A1 (ru) |
EP (1) | EP2606885B1 (ru) |
JP (1) | JP2014513721A (ru) |
KR (1) | KR20140033123A (ru) |
CN (1) | CN103561735B (ru) |
EA (1) | EA021496B1 (ru) |
WO (1) | WO2012158002A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2659708C1 (ru) * | 2017-08-28 | 2018-07-03 | Олег Викторович Грачев | Композиция для лечения заболеваний вирусной и кокковой этиологии |
CN110974776B (zh) * | 2019-11-22 | 2023-02-28 | 东南大学 | 一种碘-淀粉气凝胶及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545401A (en) | 1994-06-02 | 1996-08-13 | Shanbrom; Edward | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine |
EP0823996A1 (en) | 1996-08-15 | 1998-02-18 | Yuugen Kaisha Aics Laboratory Sangyo | Anti-infective against STD relating, for example, to HIV, Chlamydia, gonococcus, treponema pallidum or herpes simplex and device used to preserve/mix principal ingredient and base of such anti-infective |
KZ6730B (ru) * | 1996-01-26 | 1998-11-16 | ||
KZ13765A (ru) * | 2002-12-03 | 2003-12-15 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955101A (en) * | 1991-03-28 | 1999-09-21 | 943038 Ontario Inc. | Dry starch-iodine pharmaceutical formulations |
US5885592A (en) * | 1997-10-29 | 1999-03-23 | Symbollon Corporation | Methods and pharmaceutical compositions for oral delivery of molecular iodine |
JP2002518351A (ja) * | 1998-06-19 | 2002-06-25 | オキシバイオ・インコーポレイテッド | 抗感染および避妊特性を有する医療装置 |
WO2001078751A1 (en) * | 2000-04-17 | 2001-10-25 | 'armenicum+' Jsc | Antiviral and antibacterial pharmaceutical preparation 'armenicum' and its use for treatment of infectious diseases |
US20030211173A1 (en) * | 2002-05-08 | 2003-11-13 | Veach Tom C. | Lubrication composition |
-
2011
- 2011-11-10 WO PCT/KZ2011/000018 patent/WO2012158002A1/ru active Application Filing
- 2011-11-10 EP EP11865767.5A patent/EP2606885B1/en not_active Not-in-force
- 2011-11-10 CN CN201180070015.XA patent/CN103561735B/zh not_active Expired - Fee Related
- 2011-11-10 EA EA201300096A patent/EA021496B1/ru not_active IP Right Cessation
- 2011-11-10 JP JP2014511314A patent/JP2014513721A/ja active Pending
- 2011-11-10 KR KR1020137033138A patent/KR20140033123A/ko not_active Application Discontinuation
- 2011-11-10 US US14/117,857 patent/US20140072598A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545401A (en) | 1994-06-02 | 1996-08-13 | Shanbrom; Edward | Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine |
KZ6730B (ru) * | 1996-01-26 | 1998-11-16 | ||
EP0823996A1 (en) | 1996-08-15 | 1998-02-18 | Yuugen Kaisha Aics Laboratory Sangyo | Anti-infective against STD relating, for example, to HIV, Chlamydia, gonococcus, treponema pallidum or herpes simplex and device used to preserve/mix principal ingredient and base of such anti-infective |
KZ13765A (ru) * | 2002-12-03 | 2003-12-15 |
Non-Patent Citations (10)
Also Published As
Publication number | Publication date |
---|---|
CN103561735A (zh) | 2014-02-05 |
EP2606885A1 (en) | 2013-06-26 |
EP2606885A4 (en) | 2013-07-24 |
EA021496B1 (ru) | 2015-06-30 |
JP2014513721A (ja) | 2014-06-05 |
CN103561735B (zh) | 2016-01-20 |
US20140072598A1 (en) | 2014-03-13 |
KR20140033123A (ko) | 2014-03-17 |
EP2606885B1 (en) | 2016-05-11 |
EA201300096A1 (ru) | 2013-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sorrell et al. | A prospective study of adverse reactions associated with vancomycin therapy | |
EP0139535B1 (en) | Compositions for combatting toxaemia | |
KR20010108469A (ko) | 항진균 조성물 | |
US6348190B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
US5510387A (en) | Antimicrobial interferon-inducing medicament | |
KR20070092095A (ko) | 소독용 조성물 및 이의 제조 및 이용 방법 | |
WO2012158002A1 (ru) | Лекарственный препарат «renessans», обладающий антибактериальным, противоязвенным и иммуномодулирующим действием | |
Adamson et al. | Embryotoxic effect of L-asparaginase | |
RU2368609C1 (ru) | Серебряная соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'-изоникотиноилгидразида, проявляющая иммунотропную, противомикробную, противогрибковую (противомикотическую) активность, и лекарственное средство на ее основе | |
O'Callaghan et al. | Vincristine toxicity unrelated to dose. | |
WO1991013629A1 (de) | Verwendung von lactoferrin zur bekämpfung der toxischen wirkung des endotoxins | |
Davtyan et al. | Design of iodine-lithium-α-dextrin liquid crystal with potent antimicrobial and anti-inflammatory properties | |
RU2614730C1 (ru) | Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза | |
Neter et al. | The combined antimicrobial activity of urea and sulfathiazole in urine | |
Pines et al. | A comparison of pivampicillin and ampicillin in exacerbations of chronic bronchitis | |
Schamberg et al. | Sodium Oxy-Mercury-Ortho-Nitro Phenolate (Mercurophen): With Special Reference to Its Practcal Value as a Disinfectant | |
RU2571819C2 (ru) | Иммунометаболический состав с антимикробной активностью | |
UA72286C2 (en) | Alkaline salts n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinsulfone)-n'-izonicotinoylhydrazide which can be used as antimicrobial and immunotropic agents, a method for the preparation thereof, use thereof as immunomodulator and pharmaceutical composition based thereon | |
RU2414223C1 (ru) | Средство, обладающее иммуностимулирующим и гемостимулирующим действием | |
RU2320325C1 (ru) | Способ лечения неспецифических маститов у коров | |
US11351192B2 (en) | De-colonization drug, preparation method therefor, and application thereof | |
RU2705098C2 (ru) | Фармацевтическая композиция для лечения грибковых поражений слизистых оболочек | |
Young et al. | Sulfacetimide: Toxicity and Efficacy in Gonorrhea and Urinary Tract Infections Preliminary Report | |
Young | Allergy to iprindole (Prondol) with hepatotoxicity. | |
JP4875813B2 (ja) | 抗真菌組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11865767 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201300096 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011865767 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14117857 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014511314 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137033138 Country of ref document: KR Kind code of ref document: A |